Posted on

maximus cbd oil

Industrial Hemp Plants contain less than 0.3% THC which is what allows it to be classified as a Legal Substance in the United States.

All the available evidence indicates that long term use of CBD oil causes no side effects; however, CBD oil has only truly been available for pets for a couple years. The most common reason our customers cite for using CBD is to replace prescription drugs that have a known history of long term side effects. Always consult your veterinarian and use our dosing chart/schedule to coordinate the use of CBD with prescription medications.

Rich in Natural Terpenes & Cannabinoids for a Full Entourage Effect

CBD Oil for Dogs is an all-natural plant-based extract that works by sending signals between nerve cells via a system of receptors activated by terpenes. Luckily the natural remedy inside these plants provides a great alternative terpene source, to assist the central nervous receptors, these control critical body functions such as immune response, pain sensation, appetite, memory, mood and more.

Organic: The Hemp plant has a lot of amazing benefits, and one of those is it’s great at cleaning up toxic spills. This makes it so important that you only chose CBD oil derived from organic grown hemp free of any harmful chemicals.

Take note, when giving your dog hemp extract to avoid marijuana as products high in Tetrahydrocannabinol are not safe for dogs. Make sure those levels are always lower than 0.3% for any hemp CBD Products.

They’ve not added to their profile page yet. But if they have products nearby, you can order them on Leafly!

Get perks like local deals, new strain spotlights, and a free jar of CBD:THC gummies when you sign up ($59 value)!

Is this your brand?

Join the Leafly marketplace! We’ve made it super easy to get your products in front of our millions of customers.

By providing us with your email address, you agree to Leafly’s privacy policy and terms & conditions.

This study is a single-centre, 12-week open-label trial of CBD for anxiety disorders. Participants are young people aged 12 – 25 years with a DSM-5 diagnosis of an anxiety disorder who do not respond to evidence-based standard treatment (e.g. CBT or CBT plus SSRIs/SSNRIs). CBD is administered on a fixed–flexible schedule adjusted up to a maximum dose. Each participant will be offered biweekly CBT for 12 weeks (5 sessions). The trial is being conducted at the Headspace Glenroy facility according to Good Clinical Practice guidelines, overseen by the trial sponsor, Orygen – The National Centre of Excellence in Youth Mental Health study service unit.

Chief Investigator: Professor Paul Amminger (Orygen)

This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney; and Orygen, The National Centre of Excellence in Youth Mental Health.

Project Coordinators: Dr Maximus Berger (Orygen) & Emily Li (Orygen)